Angiogenesis and angiogenic mediators in haematological malignancies

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 43-51

  Mangi, M H ^a   Newland, A C ^a  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Leukaemia; Lymphoma; Myeloma; Vascular endothelial growth factors (VEGF)

Indexed keywords

VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; BONE MARROW BIOPSY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; HEMATOLOGIC DISEASE; HEMATOPOIESIS; METASTASIS; MYELODYSPLASTIC SYNDROME; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ADULT; ANGIOGENESIS INHIBITORS; CHILD; CYTOKINES; CYTOTOXINS; ENDOTHELIAL GROWTH FACTORS; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; LYMPHOKINES; LYMPHOMA; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033763986     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02104.x     Document Type: Review

References (64)

1. Increased angiogenesis in chronic myeloid leukemia and myelodysplastic syndromes
2. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia (AML)
3. Isolation of putative progenitor endothelial cells for angiogenesis
4. Release of the angiogenic cytokines VEGF from platelets
5. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
6. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
7. Bone marrow microvascular. Structure and function
8. Predictors of pathologic stage in prostate carcinoma
9. Requirement of vascular integrin αVβ3 for angiogenesis
10. Integrin αVβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
11. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells
12. The microcirculation of the bone marrow
13. Death to a blood vessel, death to a tumor
14. Endothelial cells in physiology and pathophysiology of vascular disorders
15. Microscopic observation on the growth of blood capillaries in the living mammals
16. Behind the headlines of endostatin's ups and downs
17. Blood vessel maturation: Vascular development comes of age
18. CD31: An immunospecific marker for endothelial differentiation in human neoplasms
19. Lymphatics in primary cutaneous melanoma
20. Clinical applications of research on angiogenesis
21. Angiogenesis in cancer, vascular rheumatoid and other diseases
22. Blood vessel formation. What is the molecular basis
23. Induction of angiogenesis during the transition from hyperplasia to neoplasia
24. Intracellular pool of VEGF in human neutrophils
25. Phase I trial of recombinant humanized monoclonal antivascular endothelial growth factor (ANT-VEGF MAB) in patients with metastatic cancer
26. Dormancy of micrometastasis: Balanced proliferation and apoptosis in the presence of angiogenesis suppresion
27. A cancer therapy resistant to cancer
28. Evidence for abnormal angiogenesis in the bone marrow of patients with B-cell chronic lymphocytic leukemia (CLL)
29. Angiogenesis: Implications for rheumatoid arthritis
30. Induction of neovascularisation by activated human monocytes
31. Endothelial cell markers in vascular neoplasms: An immunohistochemical study comparing FVIIIr Ag, blood group specific antigens, 6-keto PGF1 alpha and Ulex europeus 1 lectin
32. The cells of human yolk sac blood island express CD34 and produce GM-CSF
33. Primary myelodysplastic syndromes: Diagnostic and prognostic significance of immunohistochemical assessment of bone marrow biopsies
34. Increased angiogenesis in chronic myelomonocytic leukaemia. Biologic and clinical implications
35. Cytokine regulation of endothelial cell function: From molecular level to bedside
36. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
37. Elevated levels of an angiogenic peptide, basic fibroblast growth factor in the urine of patients with wide spectrum of cancers
38. What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis
39. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
40. Initiation of hematopoiesis and vasculogenesis in murine yolk sac
41. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
42. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma
43. Angiogenesis spectrum in the stroma of B cell NHL. An immunohistochemical and ultrastructure study
44. Mechanism of angtogenesis
45. Vasculogenesis
46. Evidence for the invovement of endothelial cell integrin Vβ3 in the disruption of the tumor vasculature induced by tumor necrosis factor and interferon-gamma
47. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma
48. Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumors
49. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor
50. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma
51. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
52. Evidence for circulating bone marrow derived endothelial cell
53. Antitumor activity of thalidomide in refractory multiple myeloma
54. Suppression of p53 and p21 expression by vascular cell integrin αVβ3 during angiogenesis in vivo
55. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents
56. Bone marrow of patients with multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44
57. Progression of mycosis fungoides is associated with changes in angiogenesis and expression of matrix metalloprotelnases 2 and 9
58. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
59. CD34 a review
60. Acute lymphoblastic leukemia cells and their bone marrow stroma collaborate to induce endothelial cell proliferation thereby promoting leukemia cell survival
61. Blood platelets and serum VEGF in cancer patients
62. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase
63. Intratumor microvessel density as a prognostic factor in cancer
64. Vasculogenesis, angiogenests and growth factors: Ephrins enter the fray at the border